A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
Hoffmann-La Roche · Type 2 Diabetes Mellitus
Phase 2
Active, not recruiting
240
2026-07
Industry sponsor intelligence
Hoffmann-La RocheClinical Pipeline.
Lead-sponsor view of Hoffmann-La Roche's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 22
- Recruiting
- 0
- Active
- 4
- Completed
- 15
- Results posted
- 5
- Avg enrollment
- 353
Pipeline overview
Programs by phase and activity.
Velocity
Hoffmann-La Roche trials by start year
Study start year · indexed snapshot
Development
Trials by phase
21phase labels
Early Phase 10
Phase 10
Phase 27
Phase 34
Phase 410
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Enfuvirtide → | 18 | 0 | 4 | 3 | 10 | 0 |
| Goserelin → | 2 | 0 | 1 | 1 | 0 | 2 |
| Leuprolide → | 2 | 0 | 1 | 1 | 0 | 2 |
| Triptorelin → | 2 | 0 | 1 | 1 | 0 | 2 |
| Petrelintide → | 1 | 0 | 1 | 0 | 0 | 1 |
| Semaglutide → | 1 | 0 | 1 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight
Hoffmann-La Roche · Obesity or Overweight
Phase 2
Not yet recruiting
486
2026-07
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Hoffmann-La Roche · Early Breast Cancer
Phase 3
Active, not recruiting
4,170
2026-06
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Hoffmann-La Roche · Ovarian Cancer
Phase 2
Active, not recruiting
176
2026-06
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients
Hoffmann-La Roche · HIV Infections
Phase 2
Completed
64
2016-11
QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection
Hoffmann-La Roche · HIV Infections
Phase 4
Completed
361
2016-11
An Observational Study of Induction Therapy With Fuzeon (Enfuvirtide) in Combination With Antiretroviral Drugs in Patients With HIV-1 Infection
Hoffmann-La Roche · HIV Infections
Not applicable
Completed
58
2016-11
A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection
Hoffmann-La Roche · HIV Infections
Phase 4
Completed
6
2016-11
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
Hoffmann-La Roche · HIV Infections
Phase 4
Completed
142
2016-08
A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection
Hoffmann-La Roche · HIV Infections
Phase 4
Completed
23
2016-07
Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection
Hoffmann-La Roche · HIV Infections
Phase 3
Completed
84
2016-04
T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents
Hoffmann-La Roche · HIV Infections
Phase 2
Completed
52
2016-02
WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.
Hoffmann-La Roche · HIV Infections
Phase 4
Completed
58
2015-11
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Hoffmann-La Roche · HIV Infections
Phase 4
Completed
326
2015-11
Showing 10 of 15 studies
Search sponsor records
All Hoffmann-La Roche studies.
This page groups studies where Hoffmann-La Roche is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
22 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT07112872A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 DiabetesJul 7, 2026NCT07589686A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or OverweightJul 7, 2026NCT04961996A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Jun 17, 2026NCT04931342A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsJun 8, 2026NCT00100984A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1Jun 20, 2017NCT00089492A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected PatientsNov 2, 2016NCT00232908QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) InfectionNov 2, 2016NCT01902615An Observational Study of Induction Therapy With Fuzeon (Enfuvirtide) in Combination With Antiretroviral Drugs in Patients With HIV-1 InfectionNov 2, 2016NCT02569502A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) InfectionNov 2, 2016NCT00461266ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.Aug 24, 2016